[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2018051296A3 - Non—saponifiable compounds of natural lipids for use in the treatment of rheumatic pathologies - Google Patents

Non—saponifiable compounds of natural lipids for use in the treatment of rheumatic pathologies Download PDF

Info

Publication number
WO2018051296A3
WO2018051296A3 PCT/IB2017/055624 IB2017055624W WO2018051296A3 WO 2018051296 A3 WO2018051296 A3 WO 2018051296A3 IB 2017055624 W IB2017055624 W IB 2017055624W WO 2018051296 A3 WO2018051296 A3 WO 2018051296A3
Authority
WO
WIPO (PCT)
Prior art keywords
chronic
treatment
rheumatic
steroidal
imbalance
Prior art date
Application number
PCT/IB2017/055624
Other languages
French (fr)
Other versions
WO2018051296A2 (en
Inventor
Chiara De Gregorio
Original Assignee
Codex V Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Codex V Srl filed Critical Codex V Srl
Publication of WO2018051296A2 publication Critical patent/WO2018051296A2/en
Publication of WO2018051296A3 publication Critical patent/WO2018051296A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates in particular to a pharmaceutical composition comprising the non-saponifiable moieties obtained from lipids of natuiral vegetable origin for use in the treatment of those rheumatic diseases, such as rheumatoid arthritis and/or lupus and/or rheumatic polymyalgia and/or ankylosing spondylitis and/or psoriatic arthritis and/or SLE (Lupus Erythematosus Systemic) and/or polymyositis and/or dermatomyositis and/or osteoarthritis and/or tenosynovitis and/or gout, which are caused by the permanent (or chronic) alteration (or imbalance) of the normal physiological equilibrium of the steroidal balance and also of pathologies, such as Alzheimer's disease, scleroderma, Crohn's disease and/or Sjogren's syndrome, which are caused by the permanent (or chronic) alteration (or imbalance) of the normal physiological equilibrium of the steroidal balance in a patient suffering from this chronic pathology. Said pharmaceutical composition is particularly adapted for transdermal and/or transmucosal topical administration.
PCT/IB2017/055624 2016-09-19 2017-09-18 Non—saponifiable compounds of natural lipids for use in the treatment of rheumatic pathologies WO2018051296A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102016000093764 2016-09-19
IT102016000093764A IT201600093764A1 (en) 2016-09-19 2016-09-19 UNSAPONIFYABLE OF NATURAL LIPIDS FOR USE IN THE TREATMENT OF RHEUMATIC DISEASES

Publications (2)

Publication Number Publication Date
WO2018051296A2 WO2018051296A2 (en) 2018-03-22
WO2018051296A3 true WO2018051296A3 (en) 2018-04-26

Family

ID=58455403

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2017/055624 WO2018051296A2 (en) 2016-09-19 2017-09-18 Non—saponifiable compounds of natural lipids for use in the treatment of rheumatic pathologies

Country Status (2)

Country Link
IT (1) IT201600093764A1 (en)
WO (1) WO2018051296A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999059523A2 (en) * 1998-05-15 1999-11-25 Codex V S.R.L. Topical pharmaceutical compositions useful for the treatment of cutaneous or circulatory pathologies on inflammatory, immune, proliferative or degenerative basis
WO2001003712A1 (en) * 1999-07-09 2001-01-18 Astion Development Aps Composition containing extracts of butyrospermum parkii and the use as medicament or dietary supplement
WO2002055087A1 (en) * 2001-01-12 2002-07-18 Bsp Pharma Dihydro-triterpenes in the treatment of viral infections, cardiovascular disease, inflammation, hypersensitivity or pain
WO2002072035A2 (en) * 2001-03-14 2002-09-19 Lipogenics, Inc. Novel anti-inflammatory compositions and methods of use
WO2008114125A1 (en) * 2007-03-21 2008-09-25 Codex S.R.L. Compositions containing compounds having steroid structure and their use for inducing the proliferation and differentiation of stem cells of the organism

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6715975A (en) * 1967-11-24 1969-05-28
RU2163481C1 (en) * 2000-05-26 2001-02-27 Котикова Марина Анатольевна Fir cream-balsam and its versions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999059523A2 (en) * 1998-05-15 1999-11-25 Codex V S.R.L. Topical pharmaceutical compositions useful for the treatment of cutaneous or circulatory pathologies on inflammatory, immune, proliferative or degenerative basis
WO2001003712A1 (en) * 1999-07-09 2001-01-18 Astion Development Aps Composition containing extracts of butyrospermum parkii and the use as medicament or dietary supplement
WO2002055087A1 (en) * 2001-01-12 2002-07-18 Bsp Pharma Dihydro-triterpenes in the treatment of viral infections, cardiovascular disease, inflammation, hypersensitivity or pain
WO2002072035A2 (en) * 2001-03-14 2002-09-19 Lipogenics, Inc. Novel anti-inflammatory compositions and methods of use
WO2008114125A1 (en) * 2007-03-21 2008-09-25 Codex S.R.L. Compositions containing compounds having steroid structure and their use for inducing the proliferation and differentiation of stem cells of the organism

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANN-CHARLOTTE ANDERSSON ET AL: "Shea butter extract for bioactive skin care", 31 December 2015 (2015-12-31), XP055434494, Retrieved from the Internet <URL:http://aakpersonalcare.com/wp-content/uploads/2016/01/AAK-Shea_butter_extract_for_bioactive_skin_care-2015.pdf> [retrieved on 20171212] *

Also Published As

Publication number Publication date
IT201600093764A1 (en) 2018-03-19
WO2018051296A2 (en) 2018-03-22

Similar Documents

Publication Publication Date Title
CY1124878T1 (en) ORODIZED DOSAGE UNIT CONTAINING AN ESTETROL INGREDIENT
NI201800115A (en) PYRIDINYLTRIAZOLE DERIVATIVES SUBSTITUTED WITH AMIDE AND USES OF THESE
WO2012080727A3 (en) Casein kinase 1delta (ck1delta) inhibitors
BR112019024747A2 (en) fixed dose formulations
BR112017007460A2 (en) ror-gamma dihydropyrrolopyridine inhibitors
BR112017025108A2 (en) pyy selective compounds and uses thereof
MX2018002631A (en) Small molecule inhibitors of dyrk1a and uses thereof.
BR112015014372A8 (en) autotaxin inhibitors, their uses, and pharmaceutical composition and combination &#34;.
EP3329965A3 (en) Dosing regimen of anti-alpha4beta7-antikörper
BR112018073676A2 (en) pegylated liposomes and methods of use
BR112014032917A2 (en) compounds and therapeutic uses thereof
EA201890767A1 (en) C4-MODIFIED OLEANOLIC ACID DERIVATIVES FOR INHIBITION OF IL-17 AND OTHER APPLICATIONS
BR112018072034A2 (en) mic-1 compounds and uses thereof
BR112016028845A2 (en) compound, pharmaceutical composition and use of a compound
EA201991387A1 (en) TRICYCLIC JONES - PYRIMIDINE DERIVATIVES FOR INHIBITING ROR-γ AND OTHER APPLICATIONS
BR112015019412A2 (en) bace1 inhibitors
MX2020005518A (en) Nonracemic mixtures and uses thereof.
EP4424374A3 (en) Crystalline forms of tenofovir alafenamide
WO2012101653A3 (en) Modified release pharmaceutical compositions memantine
BR112017009510A2 (en) compositions comprising cyclosporine
EA202192199A1 (en) COMPOSITIONS CONTAINING CINNAMIC ACID AND METHODS OF THEIR APPLICATION
UA112420C2 (en) APOPTOSIS INHIBITORS AND THEIR APPLICATIONS
WO2017093810A3 (en) Composition for intraoral delivery of biologically active peptides and proteins
PH12018502703A1 (en) An oxazine derivative for use in the prevention of alzheimer&#39;s disease in at risk patients
WO2018051296A3 (en) Non—saponifiable compounds of natural lipids for use in the treatment of rheumatic pathologies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17784010

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17784010

Country of ref document: EP

Kind code of ref document: A2